British pharma giant says that a Federal Circuit decision could stifle competition by lowering the bar for proving patent ...

Market leader settles patent disputes with generic drug makers, blocking the release of versions of two key products | More than 80% of HIV patients in the US use Gilead’s treatments.

5 March 2024 The drama of the decade-long patent dispute reflects a changing market. Marisa Woutersen speaks with John Cronin ...

David Por joins the firm’s Paris team as partner | New hire brings two decades of experience, including in healthcare and ...

The former USPTO director has filed her first amicus brief since rejoining private practice, arguing that instructions issued ...

If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

The company’s key Eylea treatment patents faced intense scrutiny as the US Federal Circuit heard Williams & Connolly, RMMS Legal, and McGuireWoods argue over criticality, stability, and validity.

Court of Appeal says in-house representatives can appear before the court | Patent attorneys with ‘administrative and financial powers’ or own shares remain barred | Decision specific to Microsoft v ...